Imagine if we could grow the 'glue' our blood uses to stop leaks in a lab instead of relying on human donors. This technology creates a clean, synthetic version of these proteins that is safer and more consistent. It allows doctors to pick specific types of 'glue' for different medical needs, like stopping a bleed or protecting an implant from germs.
Current haemostasis products rely on donor plasma, which carries risks of disease transmission, suffers from low purity, and is subject to volatile global supply chains and import restrictions.
A recombinant manufacturing platform using CHO cells and patented purification to produce functional human fibrinogen and thrombin.
If you are a manufacturer dealing with the risks and supply chain instability of donor-derived blood products — this project developed RecoSeel, a bioactive topical haemostat that stops excessive bleeding during surgery with higher purity and stability.
If you are a developer dealing with antibiotic-resistant biofilms on implants — this project developed RecoCoat, an anti-microbial coating that reduces the development of MRSA bacterial biofilms.
If you are a pharma company dealing with the high cost and low purity of plasma-derived proteins — this project developed a recombinant manufacturing platform to supply rhFib variants and rhThr as OEM products.
The RECOFIB platform aims to bring functional recombinant fibrinogen and active thrombin to market at a commercially acceptable cost, specifically offering lower production costs for recombinant thrombin (rhThr).
Yes, the platform uses Chinese Hamster Ovary (CHO) expression technology and proprietary upstream purification processes designed for commercially viable manufacturing.
The project utilizes patented upstream purification processes to produce fully intact and functional recombinant proteins.
By replacing donor blood/plasma, it eliminates the risk of blood-borne disease transmission and removes dependence on US plasma imports.
It is designed as a coating (RecoCoat) for medical devices or as a topical application (RecoSeel) for surgical use.
The project is led by a single Dutch SME, FIBRIANT BV, which maintains 100% industry control. This lean structure suggests a direct path to commercialization without the complexities of academic partnerships, focusing entirely on the industrial application of the RECOFIB platform.
Contact FIBRIANT BV in the Netherlands for OEM supply inquiries.
Contact us to explore licensing opportunities for the RECOFIB platform.
